Japan plans to revise its definition of “vaccines of high development priority.” The Ministry of Health, Labor and Welfare’s (MHLW)…
HOME > COMMENTARY
COMMENTARY
- Global Pharmas Casting Colder Eyes on Japan Market; PhRMA, EFPIA to Up Lobbying Efforts with Govt, Ruling Parties
March 11, 2016
- Companies Can “Veto” Humanitarian Trials for Legitimate Reasons; Cooperation Is Essential, but Access Scheme Shouldn’t Stymie Main Development
February 23, 2016
- It’s Time to Squarely Discuss Proposed Penalty through Drug Price Cuts
February 3, 2016
- Generic Industry’s Tactic to Thwart 50% Pricing Rule Draws Mixed Reviews
January 18, 2016
- Is 7.8% Drug Cost Cut Justifiable? Make “Huge Seller” Re-Pricing a Starter to Discuss This
January 12, 2016
- High Hopes for New Osteoporosis Drugs, but “Treatment Gap” Needs to Be Addressed
November 27, 2015
- Sakigake Designation System to Link Regulatory and Drug Pricing Systems; Could Result in Tougher Scrutiny for Designated Products
November 6, 2015
- Data from Humanitarian Trials to Be Used in Product Reviews; Effective Use of Safety-Related Information Will Be Key
October 13, 2015
- Japan, US, EU Regulators Trod Different Paths to Iressa Approval; Japan’s Capabilities to Be Tested with Sakigake System
September 24, 2015
- How Will Industry Counter Proposed Re-Pricing of “Huge Seller” Drugs?
August 18, 2015
- Leaner Sales Forces? Lower Profits? Drug Makers Face Tough Decision in 80% Generic Era
August 14, 2015
- PMDA Poised to Tap Big Data to Refine Reviews, Safety Steps; Dedicated Center Eyed in 2018
August 12, 2015
- Wholesalers Face Pressing Need to Retool Biz Strategy as Generics Gain Ground
July 21, 2015
- Viable Third-Party Review System Required for Drug Makers’ Advertisements
July 7, 2015
- Japan Compassionate Use System a “Stick” for Drug Makers? Incentives to Counter Their Burden Needed
June 22, 2015
- Generic Makers Baffled by New Govt Target, Quality and Supply Concerns Linger
June 15, 2015
- Thorny Path Ahead toward Trial Rollout of Cost-Effective Assessment in FY2016; Chuikyo to Begin Discussions on May 27
May 26, 2015
- 1 Year after Viagra Generic Debut, Freely Priced Generics Seem to Be Bringing Benefits
May 8, 2015
- Opdivo Offers Hope but Poses Challenges Too, Cautious Approach Needed to Expand Indications
April 27, 2015
- Will Japanese Drug Makers Become More Discerning in Unearthing Seeds?
April 17, 2015
ページ
As CEO of Morunda, I had the privilege of interviewing Bill Schuster, Country Manager of Viatris in South Korea. Our conversation delved into the multifaceted nature of leadership in the healthcare industry, exploring challenges, successes, and the power of authenticity.A…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…